ACAD
37.59
-0.04
-0.11%
AEMD
1.92
+0.17
+9.41%
APRI
1.68
+0.02
+1.50%
ARNA
25.09
-0.02
-0.08%
ATEC
2.19
+0.06
+2.82%
CNAT
5.38
-0.15
-2.71%
CRXM
0.151
0.00
0.00%
CYTX
0.39
-0.02
-4.79%
DXCM
69.99
+0.49
+0.71%
GNMK
9.52
-0.04
-0.42%
HALO
16.78
+0.18
+1.08%
ILMN
201.41
+1.17
+0.58%
INNV
0.097
-0.003
-3.15315%
INO
6.15
-0.14
-2.23%
ISCO
1.85
+0.05
+2.78%
ISIS
57.56
0.00
0.00%
LGND
135.55
-0.26
-0.19%
LPTN
2.93
-2.93
-100.00%
MBVX
0.67
-0.07
-9.4730%
MEIP
2.75
+0.01
+0.36%
MNOV
6.18
+0.3
+5.10%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.93
+0.1
+0.17%
NUVA
54.25
-0.36
-0.66%
ONCS
0.97
-0.01
-1.01%
ONVO
1.97
-0.04
-1.99%
OREX
2.12
-0.17
-7.22%
OTIC
3.3
-0.15
-4.35%
QDEL
43.1
-0.03
-0.07%
RCPT
231.96
0.00
0.00%
RGLS
1.31
-0.01
-0.76%
RMD
77.38
+0.06
+0.08%
SCIE
0
0.00
-50.0000%
SPHS
2.25
+0.01
+0.45%
SRNE
1.8
0.00
0.00%
TROV
0.7
+0.02
+2.93%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
14.4
+1.35
+10.34%
ACAD
37.59
-0.04
-0.11%
AEMD
1.92
+0.17
+9.41%
APRI
1.68
+0.02
+1.50%
ARNA
25.09
-0.02
-0.08%
ATEC
2.19
+0.06
+2.82%
CNAT
5.38
-0.15
-2.71%
CRXM
0.151
0.00
0.00%
CYTX
0.39
-0.02
-4.79%
DXCM
69.99
+0.49
+0.71%
GNMK
9.52
-0.04
-0.42%
HALO
16.78
+0.18
+1.08%
ILMN
201.41
+1.17
+0.58%
INNV
0.097
-0.003
-3.15315%
INO
6.15
-0.14
-2.23%
ISCO
1.85
+0.05
+2.78%
ISIS
57.56
0.00
0.00%
LGND
135.55
-0.26
-0.19%
LPTN
2.93
-2.93
-100.00%
MBVX
0.67
-0.07
-9.4730%
MEIP
2.75
+0.01
+0.36%
MNOV
6.18
+0.3
+5.10%
MRTX
9.85
-0.5
-4.83%
MSTX
0.13
-0.01
-5.28%
NBIX
58.93
+0.1
+0.17%
NUVA
54.25
-0.36
-0.66%
ONCS
0.97
-0.01
-1.01%
ONVO
1.97
-0.04
-1.99%
OREX
2.12
-0.17
-7.22%
OTIC
3.3
-0.15
-4.35%
QDEL
43.1
-0.03
-0.07%
RCPT
231.96
0.00
0.00%
RGLS
1.31
-0.01
-0.76%
RMD
77.38
+0.06
+0.08%
SCIE
0
0.00
-50.0000%
SPHS
2.25
+0.01
+0.45%
SRNE
1.8
0.00
0.00%
TROV
0.7
+0.02
+2.93%
VICL
2.41
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
14.4
+1.35
+10.34%
Home » Bio: Kevin Tays

Bio: Kevin Tays

Kevin is currently Associate Director of Project Management at Janssen Research & Development, LLC. He is the Early Therapeutic Area Leader (ETAL) for the Immunology portfolio and the Program Management Leader on both small and large molecule programs targeting Pulmary, Psoriasis, and Rheumatoid Arthritis indications. Kevin has been a Program Manager at Janssen since early 2008 and has supported several programs in different therapeutic indications. Prior to his Project Management role Kevin spent 8 years in the Immunology discovery group at Janssen as a medicinal chemist and is an inventor on over 20 patents. Prior to joining Janssen, Kevin began his career in the biotech sector in 1995 at Guilford Pharmaceuticals in Baltimore, MD. He earned his B.S. and MS degrees in chemistry from Brock University in St. Catharine’s Canada and completed an MBA at The Paul Merage School of Buinsess, University of California Irvine.

Be Sociable, Share!